ArticleBiofouling2016
Polysorbates prevent biofilm formation and pathogenesis of Escherichia coli O104:H4.
Article in Biofouling, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Besifloxacin-Loaded Nanostructured Lipid Carrier for Ocular Delivery: Formulation Optimization, In Vitro Characterization, and Safety Assessment.AAPS PharmSciTech · 2026Article
- Directing microbial co-culture composition using cybernetic control.Cell reports methods · 2025Article
- Non disseminative nano-strategy against in vivo Staphylococcus aureus biofilms.NPJ biofilms and microbiomes · 2023Article
- The emergence of the tetrathionate reductase operon in the Escherichia coli/Shigella pan-genome.MicrobiologyOpen · 2022Article
- Prevalence and Implications of Shiga Toxin-ProducingPathogens (Basel, Switzerland) · 2022Review
- Antibiofilm Combinatory Strategy: Moxifloxacin-Loaded Nanosystems and EncapsulatedPharmaceutics · 2022Article
- Synthetic and biological surfactant effects on freshwater biofilm community composition and metabolic activity.Applied microbiology and biotechnology · 2022Article
- Screening of Surfactants for Improved Delivery of Antimicrobials and Poly-Lactic-Pharmaceutics · 2021Article
- Review
- Surfactants: Role in biofilm management and cellular behaviour.International wound journal · 2019Article
- Inhibitory effects of polysorbate 80 on MRSA biofilm formed on different substrates including dermal tissue.Scientific reports · 2019Article
- Use of design of experiments to optimize the production of microbial probiotic biofilms.PeerJ · 2018Article
- Killing of Serratia marcescens biofilms with chloramphenicol.Annals of clinical microbiology and antimicrobials · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Escherichia coli biotype O104:H4 recently caused the deadliest E. coli outbreak ever reported. Based on prior results, it was hypothesized that compounds inhibiting biofilm formation by O104:H4 would reduce its pathogenesis. The nonionic surfactants polysorbate 80 (PS80) and polysorbate 20 (PS20) were found to reduce biofilms by ≥ 90% at submicromolar concentrations and elicited nearly complete dispersal of preformed biofilms. PS80 did not significantly impact in vivo colonization in a mouse infection model; however, mice treated with PS80 exhibited almost no intestinal inflammation or tissue damage while untreated mice exhibited robust pathology. As PS20 and PS80 are classified as 'Generally Recognized as Safe' (GRAS) compounds by the Food and Drug Administration (FDA), these compounds have clinical potential to treat future O104:H4 outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.